ABT-894
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
ABT‐126 is a novel, safe, and well‐tolerated α7 nicotinic receptor agonist in a Phase 2 Alzheimer's disease study. We tested the…
Levodopa‐induced dyskinesias (LIDs) are a serious complication of levodopa therapy for Parkinson's disease for which there is…
Previous studies in Parkinsonian rats and monkeys have shown that β2-selective nicotinic acetylcholine receptor (nAChR) agonists…
Introduction: Psychostimulants are first-line treatments for attention-deficit/hyperactivity disorder (ADHD), but their…
Abstract 1. Metabolism and disposition of ABT-894 was investigated in hepatocytes, in mice and monkeys receiving [14C]ABT-894. 2…
Dysregulation of the neuronal nicotinic acetylcholine receptor (NNR) system has been implicated in attention-deficit…